dihydroethidium has been researched along with sulfaphenazole in 1 studies
| Studies (dihydroethidium) | Trials (dihydroethidium) | Recent Studies (post-2010) (dihydroethidium) | Studies (sulfaphenazole) | Trials (sulfaphenazole) | Recent Studies (post-2010) (sulfaphenazole) |
|---|---|---|---|---|---|
| 308 | 3 | 99 | 365 | 8 | 96 |
| Protein | Taxonomy | dihydroethidium (IC50) | sulfaphenazole (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 1.3731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, N; Granville, DJ; Hunter, AL; Laher, I | 1 |
1 other study(ies) available for dihydroethidium and sulfaphenazole
| Article | Year |
|---|---|
Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Endothelium, Vascular; Enzyme Inhibitors; Ethidium; Fluorescent Dyes; Heart; In Vitro Techniques; Ischemia; Male; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Steroid 21-Hydroxylase; Sulfaphenazole; Vascular Diseases | 2005 |